MCM
RARE icon

MV Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

MV Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378 Sell
18
-10
-36% -$225 ﹤0.01% 1010
2025
Q4 		$644 Sell
28
-40
-59% -$1.31K ﹤0.01% 887
2025
Q3 		$2.05K Buy
68
+52
+325% +$1.56K ﹤0.01% 705
2025
Q2 		$582 Buy
16
+12
+300% +$433 ﹤0.01% 833
2025
Q1 		$145 Sell
4
-4
-50% -$166 ﹤0.01% 955
2024
Q4 		$337 Buy
8
+7
+700% +$347 ﹤0.01% 852
2024
Q3 		$56 Sell
1
-1
-50% -$51 ﹤0.01% 1011
2024
Q2 		$83 Buy
2
+1
+100% +$43 ﹤0.01% 915
2024
Q1 		$47 Buy
+1
New +$47 ﹤0.01% 820

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

MV Capital Management's RARE Position: Q1 2026 in Review

MV Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 36% in Q1 2026, selling an estimated $225 and leaving 18 shares worth $378. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

MV Capital Management first reported a position in RARE in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.05K in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • MV Capital Management held 18 shares of Ultragenyx Pharmaceutical worth $378 as of Q1 2026.
  • MV Capital Management sold 10 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $225.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of MV Capital Management's portfolio in Q1 2026, its #1010 holding.
  • MV Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
  • MV Capital Management's Ultragenyx Pharmaceutical position peaked at $2.05K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.